Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary

  Ovarian Neoplasms

  Free Subscription


2 Ann Oncol
5 BMC Cancer
1 Cancer
1 Cancer Lett
2 Cancer Res
2 Clin Cancer Res
2 Eur J Obstet Gynecol Reprod Biol
9 Gynecol Oncol
1 Int J Cancer
1 J Clin Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Oncol

  1. LORUSSO D, Pignata S, Gonzalez-Martin A
    Chemotherapy-free treatments: are we ready for prime time?
    Ann Oncol. 2019;30:497-498.
    PubMed     Text format    

  2. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Text format     Abstract available

    BMC Cancer

  3. STUKAN M, Badocha M, Ratajczak K
    Development and validation of a model that includes two ultrasound parameters and the plasma D-dimer level for predicting malignancy in adnexal masses: an observational study.
    BMC Cancer. 2019;19:564.
    PubMed     Text format     Abstract available

  4. MOHAMED NE, Hay T, Reed KR, Smalley MJ, et al
    APC2 is critical for ovarian WNT signalling control, fertility and tumour suppression.
    BMC Cancer. 2019;19:677.
    PubMed     Text format     Abstract available

  5. DE SABANDO AR, Lafuente EU, Garcia-Amigot F, Sanchez AA, et al
    Correction to: Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    BMC Cancer. 2019;19:1227.
    PubMed     Text format     Abstract available

  6. KAJIYAMA H, Suzuki S, Yoshikawa N, Kawai M, et al
    Fertility-sparing surgery and oncologic outcome among patients with early-stage ovarian cancer ~propensity score- matched analysis~.
    BMC Cancer. 2019;19:1235.
    PubMed     Text format     Abstract available

  7. TSAOUSIS GN, Papadopoulou E, Apessos A, Agiannitopoulos K, et al
    Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    BMC Cancer. 2019;19:535.
    PubMed     Text format     Abstract available


  8. TEMKIN SM, Mallen A, Bellavance E, Rubinsak L, et al
    The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions.
    Cancer. 2018 Dec 20. doi: 10.1002/cncr.31911.
    PubMed     Text format     Abstract available

    Cancer Lett

  9. LIU W, Wang W, Wang X, Xu C, et al
    Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis.
    Cancer Lett. 2019;472:59-69.
    PubMed     Text format     Abstract available

    Cancer Res

  10. NACARELLI T, Fukumoto T, Zundell JA, Fatkhutdinov N, et al
    NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer.
    Cancer Res. 2019 Dec 19. pii: 0008-5472.CAN-19-2830.
    PubMed     Text format     Abstract available

  11. MCCORMICK PN, Greenwood HE, Glaser M, Maddocks ODK, et al
    Assessment of Tumor Redox Status through (S)-4-(3-[(18)F]fluoropropyl)-L-Glutamic Acid PET Imaging of System xc (-) Activity.
    Cancer Res. 2019;79:853-863.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  12. LHEUREUX S, Tinker AV, Clarke BA, Ghatage P, et al
    A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1244.
    PubMed     Text format     Abstract available

  13. LANG JD, Hendricks WPD, Orlando KA, Yin H, et al
    Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition.
    Clin Cancer Res. 2018 Feb 9. pii: 1078-0432.CCR-17-1928.
    PubMed     Text format     Abstract available

    Eur J Obstet Gynecol Reprod Biol

  14. NASIOUDIS D, Wilson E, Mastroyannis SA, Latif NA, et al
    Prognostic significance of elevated pre-treatment serum CA-125 levels in patients with stage I ovarian sex cord-stromal tumors.
    Eur J Obstet Gynecol Reprod Biol. 2019;238:86-89.
    PubMed     Text format     Abstract available

  15. LECOINTRE L, Velten M, Lodi M, Saadeh R, et al
    Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN).
    Eur J Obstet Gynecol Reprod Biol. 2019;245:64-72.
    PubMed     Text format     Abstract available

    Gynecol Oncol

  16. KURODA T, Ogiwara H, Sasaki M, Takahashi K, et al
    Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31559.
    PubMed     Text format     Abstract available

  17. TATEBE K, Hasan Y, Son CH
    Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
    Gynecol Oncol. 2019 Oct 11. pii: S0090-8258(19)31541.
    PubMed     Text format     Abstract available

  18. ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
    Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31565.
    PubMed     Text format    

  19. O'CEARBHAILL RE, Deng W, Chen LM, Lucci JA 3rd, et al
    A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: A
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31536.
    PubMed     Text format     Abstract available

  20. FEHNIGER JE, Berger AA, Juckett L, Elvin J, et al
    Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
    Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31561.
    PubMed     Text format     Abstract available

  21. AREND RC, Davis AM, Chimiczewski P, O'Malley DM, et al
    EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low g
    Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31786.
    PubMed     Text format     Abstract available

  22. KAY AH, Venn M, Urban R, Gray HJ, et al
    Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31839.
    PubMed     Text format     Abstract available

  23. WAMBECKE A, Ahmad M, Lambert B, Joly F, et al
    The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 26. pii: S0090-8258(19)31841.
    PubMed     Text format     Abstract available

  24. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
    Gynecol Oncol. 2019 Dec 16. pii: S0090-8258(19)31799.
    PubMed     Text format    

    Int J Cancer

  25. RAMRAJ SK, Elayapillai SP, Pelikan RC, Zhao YD, et al
    Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32830.
    PubMed     Text format     Abstract available

    J Clin Oncol

  26. FONSECA A, Xia C, Lorenzo AJ, Krailo M, et al
    Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2019;37:396-402.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.